Lexicon Pharmaceuticals, Inc. (LXRX) Special Call June 25, 2012 10:00 a.m. ET Executives Wade Walke - Senior Director, Communications and Investor Relations Arthur Sands - President and Chief Executive Officer Brian Zambrowicz - Executive Vice President and Chief Scientific Officer Pablo Lapuerta - Senior Vice President of Clinical Development and Chief Medical Officer Jeff Wade - Executive Vice President and Chief Financial Officer Analysts Cory Kasimov - JPMorgan Alan Carr - Needham & Company Liana Moussatos - Wedbush Securities David Friedman - Morgan Stanley Kevin Kedra - Gabelli & Company Nicholas Bishop - Cowen and Company PresentationOperator
Thank you for holding. Welcome to the Lexicon Pharmaceuticals conference call and webcast to discuss LX4211 top-line Phase 2b study results. At this time all participants are in a listen-only mode. There will be a question-and-answer session to follow. Please be advised that this call is being recorded at Lexicon’s request. At this time I would like to introduce your host for today's call, Wade Walke, Senior Director of Communications and Investor Relations. Please go ahead, Dr. Walke. Wade Walke Good morning, and welcome to the Lexicon Pharmaceuticals conference call and webcast. I am Wade Walke and with me today are Dr. Arthur Sands, Lexicon’s President and Chief Executive Officer; Dr. Brian Zambrowicz, Lexicon’s Executive Vice President and Chief Scientific Officer; Dr. Pablo Lapuerta, Lexicon’s Senior Vice President of Clinical Development and Chief Medical Officer. We expect that you have seen the copy of our press release that was distributed this morning. During this call we will review the information provided in the release, provide further detail on the top line results from the LX4211 Phase 2b study, then use the remainder of our time to answer your questions. If you would like to view the slides for today's call, please access the Lexicon website at www.lexpharma.com, you will see a link on the home page for today's webcast.